T. Rowe Price Associates, Inc. 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 1:22 pm Sale | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 392,004 0.600% | -2,166,476 (-84.68%) | Filing |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 2,558,480 5.200% | -366,773 (-12.54%) | Filing |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 2,925,253 6.000% | -1,159,545 (-28.39%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 4,084,798 8.400% | 4,084,798 (New Position) | Filing |